SCHEMBL24012829

SCHEMBL24012829

CC(C)c1cnc2[nH]cc(CO)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
ALOX5AP P20292 2/20 0.39
MTNR1A P48039 2/20 0.39
MTNR1B P49286 1/20 0.39
FEN1 P39748 1/20 0.38
CLK1 P49759 3/20 0.37
DYRK1A Q13627 3/20 0.37
CYP3A4 P08684 4/20 0.36
MAP4K1 Q92918 3/20 0.36
HTR1D P28221 2/20 0.36
GPR84 Q9NQS5 1/20 0.36
SGK1 O00141 2/20 0.36
HASPIN Q8TF76 1/20 0.35
ABL1 P00519 1/20 0.35
HTR1B P28222 1/20 0.35
DYRK2 Q92630 2/20 0.34
DYRK1B Q9Y463 2/20 0.34
GSK3B P49841 1/20 0.33
CAMKK2 Q96RR4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15934118 0.79 CYP3A4 (0.46) PRMT5WDR77ALOX5APMTNR1AMTNR1B
SCHEMBL84584 0.77 MET (0.42) PRMT5WDR77
SCHEMBL13976070 0.77 PRMT5 (0.43) PRMT5WDR77CLK1DYRK1AHTR1D
SCHEMBL19286222 0.76 CYP3A4 (0.42) PRMT5WDR77ALOX5APMTNR1AMTNR1B
SCHEMBL84420 0.76 MAP3K12 (0.41) PRMT5WDR77
SCHEMBL84406 0.76 AXL (0.43) PRMT5WDR77CLK1DYRK1ASGK1
SCHEMBL19105605 0.76 MAP3K12 (0.41) PRMT5WDR77CLK1DYRK1AHTR1D
SCHEMBL15932318 0.75 ALOX5AP (0.44) PRMT5WDR77ALOX5APMTNR1AMTNR1B
SCHEMBL18352451 0.73 MAP3K12 (0.35) CLK1DYRK1ASGK1CAMKK2
SCHEMBL3709137 0.72 CYP3A4 (0.40) CYP3A4MAP4K1HTR1DABL1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders 1ST Biotherapeutics, Inc. (KR) 2023-10-31 US disclosed
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS 1ST Biotherapeutics, Inc. 2021-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802126-B2 Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders SMN1; SMN2, SNCA, HTT PRMT5 691/4885WDR77 2375/4885ALOX5AP 3256/4885
US-20210347774-A1 IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS SMN1; SMN2, SNCA, HTT PRMT5 691/4885WDR77 2375/4885ALOX5AP 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.